Australia’s leading medical research organisation has determined that puberty blockers are appropriate for the gender-affirming care of children in certain circumstances, following a year-long review of international evidence.
The federal government commissioned the Commonwealth-funded National Health and Medical Research Council (NHMRC) last year to develop the guidance, in response to bans on the treatments in Queensland and Northern Territory public hospitals introduced by their respective governments.
New Zealand later followed suit, despite widespread opposition within the health sector and warnings that the bans would harm children.
The NHMRC’s interim national clinical practice guidelines, released on Monday, recommend the conditional use of puberty suppressants for children — a position that could increase pressure on state and territory governments to reconsider their stance.
The council explicitly rejected alternative approaches to gender-affirming care advanced by critics of the model — such as the “wait and see” approach — describing it as a form of withheld care that “can affect the young person’s physical and mental health, wellbeing, and ability to function.”
Puberty blockers are a class of medication that halts the body’s production of oestrogen and testosterone.
Hormone replacement therapy, by contrast, uses synthetic hormones to replace those the body naturally produces, and is used to treat conditions including hormonal cancers such as breast and prostate cancer, endometriosis and gender incongruence.
Both treatments are common, subsidised under the Pharmaceutical Benefits Scheme for cisgender patients, and have been used for decades.
The new NHMRC guidelines do not require a child to be in distress before being treated for gender incongruence, and recommend that a multidisciplinary team “should be determined on a case-by-case basis.”
Doctors should “prioritise the best interest and wellbeing of the young person and provide care that respects their autonomy,” the guidance states.
The guidelines describe gender incongruence as the clinical term for a difference between a person’s gender and the sex recorded for them at birth.
“It is not a mental health disorder,” the guidance notes, adding that “some young people with gender incongruence will also experience significant distress, known as gender dysphoria.”
Puberty blockers have been used to treat children for a range of conditions, including precocious puberty, since the 1970s, and have been part of gender-affirming care since the 1990s.
The NHMRC advice largely aligns with the AusPATH Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, the country’s only existing clinical guidelines for doctors.
The council is an independent statutory agency funded by the Commonwealth and one of the world’s largest medical research organisations.
Its interim advice on puberty-blocking drugs draws on recommendations from its multidisciplinary gender guideline development committee and is “supported by a systematic review of the evidence,” according to the review.
“Trans and gender-diverse young people experience unjust and avoidable health disparities arising from stigma, discrimination, and barriers to accessing health care,” the council said.
Public consultation on the interim advice, titled “Advice on the use of puberty suppressants in the care of trans and gender-diverse people aged under 18,” remains open until 18 January.
The full guidelines will address other aspects of care, including the use of gender-affirming hormones, and are expected to be released in 2028.


